At 15 years of follow-up, metabolic surgery “was not only safe” but also significantly reduced major adverse liver outcomes and decompensation in patients with metabolic dysfunction-associated steatohepatitis and compensated cirrhosis.“Previous studies suggested excellent clinical outcomes in patients with MASH and fibrosis stages 1 to 3 with improvement in both cardiac and